Within a gastric cancer cohort consisting of 38 patients with HER2-positive disease, 18 patients received ALX in combination with trastuzumab, ramucirumab and paclitaxel (ATRP), and a further 20 patients received ALX148 with trastuzumab [83]. This evidence concerns the gene ERBB2 and gastric cancer.